pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-921 |
Genomic Coordinates | chr1: 166154743 - 166154798 |
Synonyms | MIRN921, hsa-mir-921, MIR921 |
Description | Homo sapiens miR-921 stem-loop |
Comment | None |
RNA Secondary Structure | ![]() |
Mature miRNA Information | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-921 | ||||||||||||
Sequence | 2| CUAGUGAGGGACAGAACCAGGAUUC |26 | ||||||||||||
Evidence | Experimental | ||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
||||||||||
SNPs in miRNA |
|
||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | BAG4 | ||||||||||||||||||||
Synonyms | BAG-4, SODD | ||||||||||||||||||||
Description | BCL2 associated athanogene 4 | ||||||||||||||||||||
Transcript | NM_004874 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on BAG4 | |||||||||||||||||||||
3'UTR of BAG4 (miRNA target sites are highlighted) |
>BAG4|NM_004874|3'UTR 1 AAGGATTTAGAACAAAGTGGAAGCCTGTTACTAACTTGACCAAAGAACACTTGATTTGGTTAATTACCCTCTTTTTGAAA 81 TGCCTGTTGATGACAAGAAGCAATACATTCCAGCTTTCCTTTGATTTTATACTTGAAAAACTGGCAAAGGAATGGAAGAA 161 TATTTTAGTCATGAGTTGTTTTCAGTTTTCAGACGAATGAATGTAATAGGAAACTATGGAGTTACCAATATTGCCAAGTA 241 GACTCACTCCTTAAAAAATTTATGGATATCTACAAGCTGCTTCTTACCAGCAGGAGGGAAACACACTTCACACAACAGGC 321 TTATCAGAAACCTACCAGATGAAACTGGATATAATCTGAGACAAACAGGATGTGTTTTTTTAAACATCTGGATATCTTGT 401 CACATTTTTGTACATTGTGACTGCTTTCAACATATACTTCATGTGTAATTATAGCTTAGACTTTAGCCTTCTTGGACTTC 481 TGTTTTGTTTTGTTATTTGCAGTTTACAAATATAGTATTATTCTCTACTTCTTGGTACATTTTGTAGTAATATGTTTAAT 561 ATAATTATTCAAGAGACTATATTGACAGCCAGATAGTATGGCAGTTCTGAAAAAATTTATATCTTTTCACCACTTGAATA 641 TACTGCAATGTGTAGTGAGTAAATTGTCTCCCTTTTTCTATAGATCATTAGGTTAGAGTTTTTTTCTTCTTTTTTTTTTT 721 TTTTTTTTTTTACCACTTCTGCTGTTCATGGTAGTAGTGGAAGGTAAATTTGGAAATGGCATTGACATAAAATGAAAATG 801 TTTACGGACACTTTTCTTTTTTGCTTTTTTATTGTATTTGGATAAAGATCCACTTAAAAGTTATCTGTTTTTTCCTGTTT 881 TTTTTTTTTTTCCCCAAAGTGTAGTTATGTTTTCACTATTGCTGCTTCTATAGAGGGCATTGTGATAGAGAGTTACAGAT 961 GAAACATTAAATGCCACAGTGAGTAGAAATAATTACTACAAAAAGTAATAAATATGATTACTTGGTAATATCATTCTCCA 1041 TCTAAAATACTAGTTTCACCTGTGAGCAGATTTCAGCTCAGTTTATAGTTAAAAACAATGAGGGTAAAATGGGATTCATG 1121 CTCAGGGAATGAATCAGCCATAGTTAGAGTGGGAAATTATTATTTTCTTCATTTAAAGGTAGATTTTATGTTTATTTCCC 1201 TAAATTGCATAAGATAAAATTGTCTGTTTAATAAAAAGACATTTATTACCATTATTAACAGTCATTTTAGAGCCAAATTT 1281 AAGAAAAGGATATTGAAAGGGTCTTTATTGGCCTTGTTTGGGTAACTCTATGCTGTTAGATAGAAGAGACTTAGGTAAAT 1361 AACTTTTTATGTCTGAGGTGAGTACACAATATTGGTTCTTGGAAAAATAGCTGTTTCTTCATAAGATACCCAAGTGATAA 1441 TTTTTTTTCCCCTAGACTGTCAGGCCTATGAGTAAATACTAAATCTATTAGCTGTCCCCACTCATAAACCAAACCAAACC 1521 AATACAAACAGATGAGGAGAGGAAATGTAGTAAAAATACTGGCTGGGTCTTATGATTGGGATGAGTGATTTTATAAGATA 1601 ATATGGTGATAATTTTATTCTAGGATTTTATTTTTGGCCTAATATAGGAATGTTTAAAAAAGGCTTTTCTATGAAAATTA 1681 GAAATTTATACTTGAAATTAAAAGTCTAGAAGGGGGAGGACCTTAAAGCTAAGCTACCAGTAAGACAATGAATAATTCAG 1761 AAGAGAACACTATTCTTTTACTGACTGAGTGCCCAAGATGCCAATTTCCATGAAGTCTTGATTTATATATATGTACACAT 1841 GTTATGCACATACATGTTTGTTTTCTAACAGTTATTTTTTAAGCTTTTGAGATAATTTTAGACTTACAGAAGAGTTGTAA 1921 AAGTAGTAGAGTTCTTGTATACTCTGCACCCACCTTGCCCTTATGTTAACATCTTACGTAACAATAGAACATTTGTCAAA 2001 ATTAAGAAATTAACCTTGATATAATACTAACTAAAGTAGAAAGTTTAAAAAGTAGAGATTTTAGTCTTTTCACTAATGTC 2081 CTTTTACTGTTCCAAGACCCAGCCTTGCATTTAGCTATCATGCCTACGTCCTGTCTTCCAGTCTGTGACAGTGTATCATA 2161 ACAGGGGATACCTGATGTTGTAATGTATTTCTGGTGTTGTTAACCTTGATCACTATGCTAAGGTGGTGTCTGCTAGGATT 2241 CGCTACTGTAAACTTACTGTGTTTTCCTTGTAATTATTGAATATTTGCTGGAGATACCCGGAGACTATGCAAATGTCCCG 2321 TTTCTGCTTAAACTTTTGCTCATTTTACTATCCATTGGCAGATCTTGCTTGTGGCAGTTACTACTGTGGTGTTCTAATGG 2401 TGATTTTCTATTTCTCTCAATCCTTCTACATTTATTATTGGAATTCTTCTGTAAGGAAGAGTTGTCAGTTCTGGATTTAT 2481 ATTTTTAACTATAATAAGATATTCAGGATAAGTATAGATTTAGAACTTAAAGATGTTAAATCATGTTAAAATTATTCCAA 2561 ATACCAATATCAAAGAAAACTAAGTTGGTAATCTATCTCAGAAAATATATGAACTTAAGAAGGAAAATAGTATTTATGAT 2641 TTGTAGAATTGGTTCAACTTTTGACTTAATACTGACTTTGGACTGAATTCAAAGTTTTCTTGAAATTTCACATCTGGACT 2721 TTTTAAAGTGTCTACATTTATATTACTTTGGGGATCATTTTGTCAAAGTCTTGAATAAAGTTACCCAGTCCTGGCATGAT 2801 AAACACAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
CLIP-seq Support 1 for dataset GSM4903833 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_a |
Location of target site | NM_001204878 | 3UTR | AAAUUAACCUUGAUAUAAUACUAACUAAAGUAGAAAGUUUAAAAAGUAGAGAUUUUAGUCUUUUCACUAAUGUCCUUUUACUGUUCCAAGACCCAGCCUUGCAUUUAGCUAUCAUGCCUACGUCCUGUCUUCCAGUCU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM4903834 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_b |
Location of target site | NM_001204878 | 3UTR | ACCUUGAUAUAAUACUAACUAAAGUAGAAAGUUUAAAAAGUAGAGAUUUUAGUCUUUUCACUAAUGUCCUUUUACUGUUCCAAGACCCAGCCUUGCAUUUAGCUAUCAUGCCUACGUCCUGUCUUCCAGUCU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM4903835 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_c |
Location of target site | NM_001204878 | 3UTR | GAAAUUAACCUUGAUAUAAUACUAACUAAAGUAGAAAGUUUAAAAAGUAGAGAUUUUAGUCUUUUCACUAAUGUCCUUUUACUGUUCCAAGACCCAGCCUUGCAUUUAGCUAUCAUGCCUACGUCCUGUCUUCCAGUCU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 4 for dataset GSM4903836 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / 124_TD_21_a |
Location of target site | NM_001204878 | 3UTR | AAAUUAACCUUGAUAUAAUACUAACUAAAGUAGAAAGUUUAAAAAGUAGAGAUUUUAGUCUUUUCACUAAUGUCCUUUUACUGUUCCAAGACCCAGCCUUGCAUUUAGCUAUCAUGCCUACGUCCUGUCUUCCAGUCU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 5 for dataset GSM4903837 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / 124_TD_21_b |
Location of target site | NM_001204878 | 3UTR | ACCUUGAUAUAAUACUAACUAAAGUAGAAAGUUUAAAAAGUAGAGAUUUUAGUCUUUUCACUAAUGUCCUUUUACUGUUCCAAGACCCAGCCUUGCAUUUAGCUAUCAUGCCUACGUCCUGUCUUCCAGUCU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 6 for dataset GSM4903838 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / 124_TD_21_c |
Location of target site | NM_001204878 | 3UTR | GAUAUAAUACUAACUAAAGUAGAAAGUUUAAAAAGUAGAGAUUUUAGUCUUUUCACUAAUGUCCUUUUACUGUUCCAAGACCCAGCCUUGCAUUUAGCUAUCAUGCCUACGUCCUGUCUUCCAGUCU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 7 for dataset GSM545216 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / miR-124 transfection |
Location of target site | ENST00000287322.4 | 3UTR | UCUUUUCACUAAUGUCCUUUUACU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
63 hsa-miR-921 Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT054764 | ANGPTL1 | angiopoietin like 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT066171 | PIP4K2C | phosphatidylinositol-5-phosphate 4-kinase type 2 gamma | ![]() |
![]() |
2 | 2 | ||||||
MIRT069409 | ZFYVE21 | zinc finger FYVE-type containing 21 | ![]() |
![]() |
2 | 8 | ||||||
MIRT102284 | DNAJB9 | DnaJ heat shock protein family (Hsp40) member B9 | ![]() |
![]() |
2 | 4 | ||||||
MIRT107595 | DNAJA1 | DnaJ heat shock protein family (Hsp40) member A1 | ![]() |
![]() |
2 | 6 | ||||||
MIRT178618 | HIAT1 | major facilitator superfamily domain containing 14A | ![]() |
![]() |
2 | 2 | ||||||
MIRT182407 | TIPRL | TOR signaling pathway regulator | ![]() |
![]() |
2 | 4 | ||||||
MIRT186552 | ZBTB18 | zinc finger and BTB domain containing 18 | ![]() |
![]() |
2 | 2 | ||||||
MIRT273662 | HOXC8 | homeobox C8 | ![]() |
![]() |
2 | 2 | ||||||
MIRT283191 | C16ORF52 | chromosome 16 open reading frame 52 | ![]() |
![]() |
2 | 2 | ||||||
MIRT284890 | NFAT5 | nuclear factor of activated T-cells 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT347670 | LSM14A | LSM14A, mRNA processing body assembly factor | ![]() |
![]() |
2 | 2 | ||||||
MIRT400222 | SLC35F6 | solute carrier family 35 member F6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT403517 | ASPH | aspartate beta-hydroxylase | ![]() |
![]() |
2 | 2 | ||||||
MIRT442251 | DCTN5 | dynactin subunit 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT443023 | SDR39U1 | short chain dehydrogenase/reductase family 39U member 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT443097 | RNF20 | ring finger protein 20 | ![]() |
![]() |
2 | 2 | ||||||
MIRT444560 | TRA2B | transformer 2 beta homolog | ![]() |
![]() |
2 | 2 | ||||||
MIRT445696 | PRKG1 | protein kinase, cGMP-dependent, type I | ![]() |
![]() |
2 | 2 | ||||||
MIRT454084 | TMEM209 | transmembrane protein 209 | ![]() |
![]() |
2 | 2 | ||||||
MIRT455463 | LYPLA2 | lysophospholipase II | ![]() |
![]() |
2 | 2 | ||||||
MIRT456653 | TIFA | TRAF interacting protein with forkhead associated domain | ![]() |
![]() |
2 | 2 | ||||||
MIRT458147 | LYRM4 | LYR motif containing 4 | ![]() |
![]() |
2 | 6 | ||||||
MIRT467073 | SRRD | SRR1 domain containing | ![]() |
![]() |
2 | 4 | ||||||
MIRT467245 | SPPL2A | signal peptide peptidase like 2A | ![]() |
![]() |
2 | 2 | ||||||
MIRT468246 | SFXN4 | sideroflexin 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT471589 | PAQR5 | progestin and adipoQ receptor family member 5 | ![]() |
![]() |
2 | 19 | ||||||
MIRT476639 | G2E3 | G2/M-phase specific E3 ubiquitin protein ligase | ![]() |
![]() |
2 | 2 | ||||||
MIRT482433 | ADM | adrenomedullin | ![]() |
![]() |
2 | 10 | ||||||
MIRT486848 | PERP | PERP, TP53 apoptosis effector | ![]() |
![]() |
2 | 6 | ||||||
MIRT489656 | SHMT1 | serine hydroxymethyltransferase 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT493441 | KANSL1 | KAT8 regulatory NSL complex subunit 1 | ![]() |
![]() |
2 | 6 | ||||||
MIRT493841 | FOXN3 | forkhead box N3 | ![]() |
![]() |
2 | 4 | ||||||
MIRT501378 | RBFOX2 | RNA binding protein, fox-1 homolog 2 | ![]() |
![]() |
2 | 10 | ||||||
MIRT509679 | ATAD5 | ATPase family, AAA domain containing 5 | ![]() |
![]() |
2 | 4 | ||||||
MIRT510280 | MED28 | mediator complex subunit 28 | ![]() |
![]() |
2 | 2 | ||||||
MIRT512221 | ATXN3 | ataxin 3 | ![]() |
![]() |
2 | 6 | ||||||
MIRT514030 | BNIP2 | BCL2 interacting protein 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT521375 | RDX | radixin | ![]() |
![]() |
2 | 4 | ||||||
MIRT521444 | RAD51 | RAD51 recombinase | ![]() |
![]() |
2 | 2 | ||||||
MIRT526055 | CBR1 | carbonyl reductase 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT528658 | FUNDC2 | FUN14 domain containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT529975 | TNFAIP8L1 | TNF alpha induced protein 8 like 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT544098 | IPMK | inositol polyphosphate multikinase | ![]() |
![]() |
2 | 2 | ||||||
MIRT545579 | SNRPA1 | small nuclear ribonucleoprotein polypeptide A' | ![]() |
![]() |
2 | 2 | ||||||
MIRT547424 | MED4 | mediator complex subunit 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT548955 | CD2AP | CD2 associated protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT549537 | NDUFA6 | NADH:ubiquinone oxidoreductase subunit A6 | ![]() |
![]() |
2 | 4 | ||||||
MIRT552550 | ZFP36L2 | ZFP36 ring finger protein like 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT554640 | ROBO1 | roundabout guidance receptor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT564904 | YTHDF1 | YTH N6-methyladenosine RNA binding protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT565578 | SLC6A8 | solute carrier family 6 member 8 | ![]() |
![]() |
2 | 2 | ||||||
MIRT568312 | BAG4 | BCL2 associated athanogene 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT617891 | PTCHD3 | patched domain containing 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT621892 | TAF13 | TATA-box binding protein associated factor 13 | ![]() |
![]() |
2 | 2 | ||||||
MIRT642850 | RNF135 | ring finger protein 135 | ![]() |
![]() |
2 | 2 | ||||||
MIRT665395 | WEE1 | WEE1 G2 checkpoint kinase | ![]() |
![]() |
2 | 2 | ||||||
MIRT697879 | UBE2B | ubiquitin conjugating enzyme E2 B | ![]() |
![]() |
2 | 2 | ||||||
MIRT698492 | THOC2 | THO complex 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT701227 | OCRL | OCRL, inositol polyphosphate-5-phosphatase | ![]() |
![]() |
2 | 2 | ||||||
MIRT701872 | MPLKIP | M-phase specific PLK1 interacting protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT707045 | TRPV2 | transient receptor potential cation channel subfamily V member 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT715216 | NPVF | neuropeptide VF precursor | ![]() |
![]() |
2 | 2 |
miRNA-Drug Associations | |||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|